darleukin

Recombinant proteinexperimentalADC

Clinical trial activity

2 trials · 13 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
2
Phase 3
1
Phase 4
0

Earliest trial started Jun 30, 2018 (NCT03567889)

Timeline

2010s

  1. Jan 1, 2018

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2018

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Inorganic
No
Polymer
No
Multi-specific
No
Payload
IL2

Oral

No

Parenteral

No

Topical

No

Sources

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT03705403Phase 2Dec 1, 2018Catholic University of Sacred Heart, Rome, Ghent University, Katholieke Universiteit Leuven, Maastricht University, Netherlands Cancer Institute, Radboud University, Technical University of Dresden, Université catholique de Louvain, University of Lille, University of London, University of Tuebingen
NCT03567889Phase 3Jun 30, 2018Philogen S.p.A., University of South Florida
Showing 2 of 2 trials
Page 1 / 1

Organizations

Research & Development (13)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Catholic University of Sacred Heart, RomeAcademic/Hospital1012018
Ghent UniversityAcademic/Hospital1012018
Katholieke Universiteit LeuvenAcademic/Hospital1012018
Maastricht UniversityAcademic/Hospital1112018
Netherlands Cancer InstituteAcademic/Hospital1012018
Philogen S.p.A.For profit1112018
Radboud UniversityAcademic/Hospital1012018
Technical University of DresdenAcademic/Hospital1012018
Université catholique de LouvainAcademic/Hospital1012018
University of LilleAcademic/Hospital1012018
University of LondonAcademic/Hospital1012018
University of South FloridaAcademic/Hospital1012018
University of TuebingenAcademic/Hospital1012018
13 organizations
Page 1 / 1